Physician profile
Mark F Sasse
NPI 1427019843
$3,096.11
in general payments reported to CMS, 2019-2025
15 companies · $181 in 2025
The $181 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,829 · 2020: $101 · 2021: $46.28 · 2022: $141 · 2023: $263 · 2024: $533 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $978.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,039.51 | 2019-2025 | Sapien 3 Ultra Resilia |
| Inari Medical, INC. | $329.35 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Livanova USA, INC. | $150.24 | 2023 | Tandemlife |
| Pfizer INC. | $111.69 | 2022-2025 | |
| Abiomed | $100.44 | 2024 | Impella |
| Irhythm Technologies, INC. | $92.76 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| Novartis Pharmaceuticals Corporation | $71.83 | 2022-2024 | |
| Medtronic, INC. | $47.72 | 2023-2024 | Symplicity G3, Abre |
| E.R. Squibb & Sons, L.L.C. | $46.23 | 2023-2025 | Camzyos |
| Amgen INC. | $42.34 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $26.50 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $24.02 | 2024 | |
| Kiniksa Pharmaceuticals, Ltd. | $13.48 | 2023 | Arcalyst |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sasse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.